Tekla Life Sciences Investors

HQLNYSEFinancial Services● Active

$16.75

$-0.17(-0.98%)

Market Cap$509482999

P/E Ratio—

52W High$18.46

52W Low$12.34

Avg Volume105K

Open$17.07

Beta0.73

Free Cash Flow Financials Revenue

Tekla Life Sciences Investors (HQL) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

HQL · free cash flow · updated Jun 8, 2026

Core FCF metrics

HQL · FCF · TTM · margin & CAGR

Free cash flow was −$2.3M for FY2025 (fiscal year ending 2025-09-30) The FCF margin was -2.7%.

FY2025 Free Cash Flow−$2.3M—

Trailing 12M (TTM)−$2.3Mtrailing 4 quarters sum

FCF Margin-2.7%−$2.3M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

HQL · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$2.3M(0M)−$2.3M—-2.7%

FY2023$0(0M)$0—0.0%

FY2022$0(0M)$0—0.0%

FY2021$0(0M)$0—0.0%

FY2020$0(0M)$0—0.0%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

HQL · P/FCF · FCF yield · FCF per share

Tekla Life Sciences Investors (HQL) reported negative free cash flow of −$0.00B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-09-30

Cash flow statement summary

HQL · cash flow statement · operating / investing / financing

For FY2025, Tekla Life Sciences Investors generated −$2.3M in operating cash flow and spent 0M in capital expenditures, yielding −$2.3M in free cash flow.

Operating Activities

−$2.3M

Cash from core business operations

2025-09-30

Investing Activities

+$25.2M

CapEx, acquisitions & investments

2025-09-30

Financing Activities

−$31.6M

Buybacks, dividends & debt

2025-09-30

FCF FormulaOperating CF (−$2.3M) − |CapEx| (0M) = FCF (−$2.3M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Financial Services)

HQL vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Tekla Life Sciences InvestorsYOU

HQL

−$2.3M—-2.7%

Loss

Berkshire Hathaway Inc.

BRK-A

$25.04B+115.6%6.7%

25%

Berkshire Hathaway Inc.

Mastercard Incorporated

$16.91B+18.2%51.6%

17%

Financial Services · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Tekla Life Sciences Investors (HQL) reported free cash flow of −$2.3M for FY2025 (fiscal year ending 2025-09-30). The FCF margin was -2.7%.

Based on available data, Tekla Life Sciences Investors has maintained positive free cash flow for at least 4 fiscal year(s). FCF peaked at $118.3M in FY2011.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

HQL free cash flow · 8 questions

Tekla Life Sciences Investors free cash flow was −$2.3M for FY2025. On a trailing twelve-month (TTM) basis, free cash flow stands at −$2.3M.

HQL free cash flowHQL FCFHQL FCF 2025HQL free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Tekla Life Sciences Investors · Tekla Life Sciences Investors SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026